Analyst firms · Morgan Stanley · BAX
Morgan Stanley BAX price target and rating history
Baxter International Inc. (BAX) · Health Care
Morgan Stanley rates Baxter International Inc. (BAX) Underweight with a $30 price target, as of its latest action on Jul 15, 2024. It has published 6 rating actions on BAX since October 2021, including 1 upgrade and 2 downgrades.
- Current rating
- Underweight
- Price target
- $30
- Median target, all firms
- Too few
- Actions on BAX
- 6
Morgan Stanley price target on BAX
Every Morgan Stanley rating on BAX
- Jul 15, 2024
- May 30, 2023
- Jan 6, 2023
- Feb 18, 2022
- Jan 7, 2022
- Oct 29, 2021
How other firms rate BAX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Oct 20, 2026 | |
| Barclays | Underweight | $20 | Oct 7, 2026 |
| Citigroup | Neutral | $28 | Jul 31, 2026 |
Questions about Morgan Stanley and BAX
- What is Morgan Stanley's price target for BAX?
- Morgan Stanley's latest stated price target for Baxter International Inc. (BAX) is $30, from its action on Jul 15, 2024.
- What is Morgan Stanley's rating on BAX?
- Morgan Stanley rates BAX Underweight, a bearish rating, as of Jul 15, 2024.
- When did Morgan Stanley last change its view on BAX?
- On Jul 15, 2024, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $39 to $30.
More BAX rating histories
All Morgan Stanley ratingsBAX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.